Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial - Spiera, R F; Gordon, J K; Mersten, J N (Ann Rheum Dis, 2011)